Announcements
Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance

Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015. Available from: http://www.eurosurveillance.org / ViewArticle.aspx?ArticleId=21169


In this issue


Home Eurosurveillance Edition  2015: Volume 20/ Issue 31 Article 1
Back to Table of Contents
Download (pdf)
Next

Eurosurveillance, Volume 20, Issue 31, 06 August 2015
Rapid communications
Increased prevalence of influenza B/Victoria lineage viruses during early stages of the 2015 influenza season in New South Wales, Australia: implications for vaccination and planning
  1. Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, Pathology West, Westmead Hospital, Westmead, New South Wales, Australia
  2. Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Westmead Hospital, Westmead, New South Wales, Australia
  3. Centre for Research Excellence in Critical Infections, University of Sydney, Westmead Hospital, Westmead, New South Wales, Australia

Citation style for this article: Jennings Z, Carter I, McPhie K, Kok J, Dwyer DE. Increased prevalence of influenza B/Victoria lineage viruses during early stages of the 2015 influenza season in New South Wales, Australia: implications for vaccination and planning. Euro Surveill. 2015;20(31):pii=21201. Article DOI: http://dx.doi.org/10.2807/1560-7917.ES2015.20.31.21201
Date of submission: 22 July 2015

During the early weeks of the 2015 Australian influenza season, influenza B accounted for 67% (821/1,234) of all positive influenza tests in New South Wales. Of 81 successive influenza B viruses characterised, 33 (41%) were from children aged < 16 years; 23/81 (28%) belonged to the B/Victoria lineage. This lineage is not contained in the southern hemisphere's 2015 trivalent influenza vaccine. The significant B/Victoria lineage activity in the southern hemisphere suggests that the quadrivalent vaccine should be considered for the northern hemisphere.


The first four weeks of the 2015 influenza season in New South Wales, Australia (15 June to 12 July) have shown substantial early influenza B activity, with frequent detection of influenza B/Victoria lineage viruses, including in children (aged under 16 years). This lineage is not contained in the southern hemisphere’s 2015 [1] or the northern hemisphere’s 2015/16 trivalent influenza vaccine [2].

Prevalence of influenza B viruses in New South Wales, Australia

Data from 13 sentinel laboratories in New South Wales, Australia’s most populous state, showed that influenza B viruses accounted for 67% (821/1,234) of positive influenza tests from 15 June to 12 July 2015 [1]. Of the 1,234 subjects with laboratory-confirmed influenza, 35% (432/1,234) were children (aged under 16 years). Of the 821 influenza B cases, 336 (41%) were children (Robin Gilmour, personal communication, 4 August 2015). This is significantly greater than the overall rate of influenza in children (41% vs 35%; p = 0.007, Fisher’s exact test). Influenza B viruses detected from samples collected from individuals with an influenza-like illness were then characterised at our laboratory (one of three World Health Organization National Influenza Centres in Australia). Of the first successive 81 influenza B viruses characterised, 58 (72%) belonged to the B/Yamagata lineage. Half of 28 influenza B viruses that we characterised from 1 to 14 July belonged to the B/Yamagata lineage. This is significantly lower than the 89/94 (95%) (p<0.0001, Fisher’s exact test) observed globally for influenza B viruses characterised from 29 June to 12 July 2015 [3].

Of the 81 characterised influenza B viruses, 33 (41%) were collected from children under 16 years of age (median age: 4 years; range: 0–13) and 13 of the infections in this age group were caused by B/Victoria lineage viruses. The ages of cases from whom the virus was characterised were representative of the age distribution of all cases of confirmed influenza infection. The median age for those aged 16 or older was 56 years (range: 17–94).

We have no data on the proportion vaccinated among the cases reported in this study.

At four predominantly adult hospitals within our local health district in western Sydney, there were 88 emergency department presentations with laboratory-confirmed influenza from 1 April to 18 July 2015. Of the 88 patients, 82 (93%) were adults and six (7%) were children. A total of 41 (47%) infections were caused by influenza B; 19 (22%) were due to influenza A(H1N1), 9 (10%) to A(H3) and 19 (22%) were untyped A. Influenza B virus was detected in 37 adults and four children.

A total of 26 patients (30%) required hospital admission (22 adults and four children), including seven into high-dependency or intensive-care units. Of the 26, 16 had influenza A (including four A(H1N1), six A(H3) and six that were not subtyped) and 10 had influenza B (five B/Victoria, three B/Yamagata and two that were not characterised). Of the seven patients admitted to high-dependency or intensive-care units, five had influenza A (including two A(H1N1), one A(H3) and two untyped) and two had influenza B/Yamagata. There has been one death (due to A(H3)), and as at 23 July, three patients (two B/Yamagata and one influenza A (not subtyped)) remain mechanically ventilated. Outbreaks of influenza B virus infection belonging to both the B/Yamagata and B/Victoria lineages have also been observed in care facilities for elderly people in New South Wales [1].

This early influenza B activity in New South Wales (the Australian influenza season generally runs from June to September and peaks in August) is in contrast to the 2014/15 northern hemisphere influenza season. In Europe, influenza B occurred later in the season and was detected in 168/810 (21%) of characterised viruses: B/Victoria lineage was identified in 3/168 (2%) of influenza B viruses [4]. In the United States, influenza B viruses also appeared late in the 2014/15 season, were detected in 810/2,193 (37%) of viruses and 228/810 (28%) of the influenza B viruses typed as B/Victoria lineage [5]. This is similar to our data before but not after 1 July, although the sample size (n = 28) after that date is small.

Background

Influenza B virus infection causes considerable morbidity and mortality, including acute respiratory distress syndrome, encephalopathy, acute renal failure and myocarditis [6,7]. Two antigenically distinct influenza B virus lineages, B/Yamagata and B/Victoria, are currently co-circulating globally [3-5]. Although clinical studies have not demonstrated any major differences in disease outcomes or antiviral susceptibility [8], in vitro studies have found up to 1,000-fold difference in neuraminidase inhibitor susceptibility in viruses of the two lineages (substantially greater in B/Victoria compared with B/Yamagata lineage) [9].

Vaccination remains key in protecting the general population against influenza virus infection. Seasonal trivalent influenza vaccines contain two influenza A virus subtypes and one influenza B virus. The southern hemisphere’s trivalent influenza vaccine for the 2015 season contains A/California/7/2009 (H1N1)-like, A/Switzerland/9715293/2013 (H3N2)-like and influenza B/Phuket/3073/2013-like (B/Yamagata lineage) viruses [1]. For the first time, a quadrivalent influenza vaccine that also contains the B/Brisbane/60/2008-like virus (B/Victoria lineage) is available for the 2015 Australian influenza season [1] (but not through the Australian Government’s National Immunisation Program).

Discussion

Several hypotheses may explain the early increased detection of B/Victoria lineage viruses in Australia. There may be an absence of cross-protective antibodies against B/Victoria lineage viruses in those who have received the trivalent influenza vaccine, and there may be reduced population immunity given that B/Yamagata lineage viruses have been the predominant circulating lineage in the World Health Organization Western Pacific Region in the past few years [10]. We observed a significant proportion of influenza B virus infection in children in our study. It has been reported that children accumulate natural immunity to influenza B more slowly than to influenza A [11]. In the same seroprevalence study [11], antibodies against only a single influenza B lineage were detected in young children, suggesting that they were susceptible to viruses of the other B lineage in the absence of protective antibodies. The high proportion of B/Victoria lineage infections detected in children in New South Wales (13/33) may amplify community transmission of influenza B virus as children shed more virus and for longer periods of time than do adults [12].

The predominant circulating influenza B lineage has been different from that chosen in the trivalent vaccine in five of 10 influenza seasons from 2001 to 2010 [13]. Reduced vaccine effectiveness during influenza seasons where there has been vaccine mismatch has resulted in a greater burden of influenza B virus infection (including influenza illness, influenza-associated hospitalisations and deaths) [13]. The quadrivalent influenza vaccine has demonstrated superior immunogenicity for the influenza B lineage not contained in the trivalent influenza vaccine in children and adults [14,15], and has been shown to be cost-effective [16,17]. It remains unclear if vaccination with the trivalent vaccine offers cross-protection against the influenza B virus lineage not contained in the vaccine. Some studies, including a meta-analysis, have shown significant cross-lineage protection [18-20], while others have found little or no cross-lineage protection [21]. The methods employed to estimate vaccine effectiveness and the participants included have varied in previous studies in several ways including the following: use of different influenza vaccines (inactivated and live attenuated); use of test-negative or people with other virus diseases as controls; inclusion of individuals previously vaccinated against the other influenza B lineage not currently contained in the present season’s trivalent vaccine; and the exclusion of children. Data on influenza B lineages were not available for all participants in the studies above [19-21].

Although the sample size of the present study is small, our preliminary data suggest early and significant B/Victoria lineage virus activity in children and adults in New South Wales. The recommended influenza B component of the 2015/16 northern hemisphere’s trivalent influenza vaccine is the B/Phuket/3073/2013-like virus (B/Yamagata lineage). As there may be incomplete protection against B/Victoria lineage infection for those receiving the trivalent vaccine, our early data would suggest that a quadrivalent vaccine should be considered for the upcoming northern hemisphere influenza season (and for travellers to the southern hemisphere). This will be especially relevant if the northern hemisphere experiences early and widespread influenza B/Victoria activity similar to that being observed in the current southern hemisphere winter.


Acknowledgements
The authors would like to thank Robin Gilmour, Respiratory Epidemiologist, Health Protection NSW for supplementing epidemiological data not available in the public domain.

Conflict of interest
None declared.

Authors’ contributions
ZJ, JK, DED: data analysis, preparation and editing of manuscript; IC: characterised influenza B viruses; KM: data analysis.


References

  1. New South Wales (NSW) Ministry of Health (MoH). NSW Health Influenza Surveillance Report. Week 28: 6 to 12 July 2015. Sydney: NSW MoH; 2015. Available from: http://www.health.nsw.gov.au/Infectious/Influenza/Documents/2015/weekending-12072015.pdf
  2. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the northern hemisphere 2015-16 influenza season and development of candidate vaccine viruses for pandemic preparedness. Geneva: WHO; 2015. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/201502_qanda_recommendation.pdf?ua=1
  3. World Health Organization (WHO). Influenza update No 242. Geneva: WHO; 27 Jul 2015. Available from: http://who.int/influenza/surveillance_monitoring/updates/2015_07_27_surveillance_update_242.pdf
  4. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation, summary Europe, May 2015. Stockholm: ECDC; 2015. Available from: http://ecdc.europa.eu/en/publications/Publications/influenza-virus-characterisation-May-2015.pdf
  5. Appiah GD, Blanton L, D’Mello T, Kniss K, Smith S, Mustaquim D, et al.; Centers for Disease Control and Prevention (CDC). Influenza activity - United States, 2014-15 season and composition of the 2015-16 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2015;64(21):583-90. PMID:26042650
  6. Li WC, Shih SR, Huang YC, Chen GW, Chang SC, Hsiao MJ, et al. Clinical and genetic characterization of severe influenza B-associated diseases during an outbreak in Taiwan. J Clin Virol. 2008;42(1):45-51. http://dx.doi.org/10.1016/j.jcv.2007.11.026 PMID:18325832
  7. Paddock CD, Liu L, Denison AM, Bartlett JH, Holman RC, Deleon-Carnes M, et al. Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection. J Infect Dis. 2012;205(6):895-905. http://dx.doi.org/10.1093/infdis/jir861 PMID:22291193
  8. van der Vries E, Ip DK, Cowling BJ, Zhang JD, Tong X, Wojtowicz K, et al. Outcomes and susceptibility to neuraminidase inhibitors in individuals infected with different influenza B lineages: the Influenza Resistance Information Study. J Infect Dis. 2015. pii: jiv375. PMID: 26160744
  9. Farrukee R, Leang SK, Butler J, Lee RT, Maurer-Stroh S, Tilmanis D, et al. Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility. J Antimicrob Chemother. 2015;70(7):2004-12. PMID:25786478
  10. World Health Organization Collaborating Centre for Reference and Research on Influenza (VIDRL). Type/subtype/lineage of samples analysed at the Centre. Samples collected 1 January - 31 May 2015. Melbourne: VIDRL; 2015. [Accessed 28 Jul 2015]. Available from: http://www.influenzacentre.org/surveillance_subtypes.htm
  11. Bodewes R, de Mutsert G, van der Klis FR, Ventresca M, Wilks S, Smith DJ, et al. Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands. Clin Vaccine Immunol. 2011;18(3):469-76. http://dx.doi.org/10.1128/CVI.00396-10 PMID:21209157
  12. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza -- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2011;60(1):1-24. PMID: 21248682
  13. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8(1):81-8. http://dx.doi.org/10.4161/hv.8.1.17623 PMID:22252006
  14. Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis. 2013;207(12):1878-87. http://dx.doi.org/10.1093/infdis/jit091 PMID:23470848
  15. Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. BMC Infect Dis. 2013;13(1):343. http://dx.doi.org/10.1186/1471-2334-13-343 PMID:23883186
  16. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine. 2012;30(11):1993-8. http://dx.doi.org/10.1016/j.vaccine.2011.12.098  PMID:22226861
  17. You JH, Ming WK, Chan PK. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong. BMC Infect Dis. 2014;14(1):618. http://dx.doi.org/10.1186/s12879-014-0618-9 PMID:25420713
  18. Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11(1):153. http://dx.doi.org/10.1186/1741-7015-11-153 PMID:23800265
  19. McLean HQ, Thompson MG, Sundaram ME, Kieke BA, Gaglani M, Murthy K, et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015;211(10):1529-40. http://dx.doi.org/10.1093/infdis/jiu647 PMID:25406334
  20. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS ONE. 2014;9(3):e92153. http://dx.doi.org/10.1371/journal.pone.0092153 PMID:24667168
  21. Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter AL, Gubbay JB, et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis. 2014;210(1):126-37. http://dx.doi.org/10.1093/infdis/jiu048 PMID:24446529


Back to Table of Contents
Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.